FDA Greenlights Kythera’s Kybella
In a much anticipated approval, the FDA has given its nod to Kythera's Kybella to treat double chins.
In a much anticipated approval, the FDA has given its nod to Kythera's Kybella to treat double chins.
The expanded indication is based on clinical data showing high responder rates and results lasting up to 18 months, with no serious adverse events reported.